In this view, recent data comparing the levels of pAKT on paired tumor biopsies obtained before and after treatment with Everolimus would suggest that an increase in p-Akt with treatment is more common in patients obtaining a better response to treatment [44], possibly suggesting that induced Akt phosphorylation is not necessary a marker of resistance to mTOR inhibitors, as previously suggested. The gene discussed is AKT1; the disease is neoplasm.